University of California, San Francisco-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2022

  1. Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma

    Clinical Cancer Research, Vol. 28, Núm. 16, pp. 3537-3545

2021

  1. A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC

    Hepatology Communications, Vol. 5, Núm. 3, pp. 538-547

  2. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

    Journal of Clinical Oncology, Vol. 39, Núm. 27, pp. 2991-3001

2020

  1. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas

    Journal of Clinical Investigation, Vol. 130, Núm. 4, pp. 1879-1895

2017

  1. Iron affects Ire1 clustering propensity and the amplitude of endoplasmic reticulum stress signaling

    Journal of Cell Science, Vol. 130, Núm. 19, pp. 3222-3233